What is HCWB's current stock price?

HCWB (HCW Biologics Inc.) is currently trading at $2.89 with a market cap of $6.0M.

What sector is HCW Biologics Inc. in?

HCW Biologics Inc. (HCWB) operates in the Healthcare sector, specifically in the Biotechnology industry.

InvestLog

HCWB HCW Biologics Inc.

Healthcare

$2.89+12.02%ClosedMarket Cap: $6.0M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.05

P/S

0.91

EV/EBITDA

-10.78

DCF Value

$-7.80

FCF Yield

-190.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

99.2%

Operating Margin

-97.9%

Net Margin

-24.7%

ROE

-102.4%

ROA

-6.0%

ROIC

-38.4%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$6.5M	$4.1M	$—
Q4 null	$27.0K	$719.2K	$—
FY null	$54.2K	$-8.0M	$—
Q3 null	$15.6K	$-4.6M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

1 Strong Buy0 Buy0 Hold0 Sell0 Strong Sell

Maxim GroupBuy

2025-05-29

Trading Activity

Insider Trades

View All

Wong Hing Cdirector, 10 percent owner, officer: Chief Executive Officer

BuyTue May 20

Winer Gary Mdirector

BuyTue May 20

GARRETT SCOTT Tdirector

BuyTue May 20

Wong Hing Cdirector, 10 percent owner, officer: Chief Executive Officer

BuyFri May 09

Wong Hing Cdirector, 10 percent owner, officer: Chief Executive Officer

BuyFri May 09

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.14

HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.

Peers